A JAK2-V617F activating mutation in addition to KIT and FLT3 mutations is associated with clinical outcome in patients with t(8;21)(q22;q22) acute myeloid leukemia.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples